Articles tagged with Covid 19 Vaccines
Researchers found that initial vaccinations against the ancestral SARS-CoV-2 strain shape immune responses to newer variants BA.5 and XBB, with higher B cell repertoire leading to more effective cross-reactive immunity. This 'immunological imprinting' effect could impact future vaccine designs.
Researchers developed a protein-based vaccine candidate called SpyCage that induces an immune response in rodent models, clearing COVID-19 infections more quickly than controls. The platform has the potential to prevent infection and transmission of respiratory viruses like SARS-CoV-2 by inducing a mucosal immune response.
A recent study found that newer monovalent COVID vaccines generated higher levels of antibodies against a range of Omicron variants, including the XBB and BQ.1.1 strains. The researchers also discovered that these vaccines increased mucosal antibody production, but not neutralizing antibody levels in the nasal cavity.
Researchers found that T cells can reshape their memory and maintain diversity against COVID-19 variants in response to successive mRNA vaccinations. The study revealed a shift among clonotypes, with a change from early responders to main responders after the second shot, suggesting a new dominant population of effector-memory T cells.
A landmark study published in JAMA Pediatrics found that COVID vaccines are safe to administer during pregnancy, with no abnormal delays in infants when tested at 12 months and 18 months. The study of over 2,200 infants from across the country also found an increased risk of delay among male infants at 12 months but not at 18 months.
A recent study published in Lancet Infectious Diseases found that vaccinated individuals had a lower risk of severe COVID-19 outcomes compared to unvaccinated individuals. The study also showed significant reductions in hospitalization and death rates from COVID-19, particularly among older individuals and those with compromised immune...
A simulation model predicts that frequent booster vaccination is highest effective for those over 65 years old and the immunocompromised to prevent severe disease. The model suggests that annual or twice-yearly boosters reduce severe infections in these high-risk populations by half.
Researchers at MIT have developed a new type of nanoparticle that can both deliver vaccines and act as an adjuvant to generate a strong immune response. The particles, called metal-organic frameworks (MOFs), were shown to be effective in delivering the SARS-CoV-2 spike protein and boosting the immune system's response.
Researchers at FAU investigated a man who received over 200 Covid-19 vaccinations, finding that his immune system remained fully functional and even showed higher concentrations of antibodies against SARS-CoV-2. No negative effects were observed on the immune response against other pathogens.
A large binational study found that SARS-CoV-2 infection was associated with an increased risk of autoimmune inflammatory rheumatic diseases (AIRDs) extending up to 12 months after infection. Vaccination showed some protection against AIRDs, particularly among those who were vaccinated.
A recent study found that the latest COVID-19 booster shot significantly reduces adults' risk of moderate or severe disease. The study analyzed data from September 2023 to January 2024 and showed that the updated vaccine provided protection against emergency department visits and hospitalizations, with a reduction of over half.
Researchers at Oregon Health & Science University found that COVID-19 vaccination during the first half of the menstrual cycle can cause slight, temporary changes in cycle length. This effect typically resolves after vaccination.
A recent MSU-co-authored study identifies 10 insights to reduce vaccine hesitancy on social media, emphasizing the importance of messaging tailored to specific groups, correcting misinformation, and leveraging trust in vaccination campaigns. The research aims to alleviate bias and improve vaccine uptake behaviors.
Researchers propose renaming VAERS as the Vaccine Safety Sentinel to reduce misinformation, citing a lack of public understanding of the system's unverified reports. They also recommend improving the system with raw data and expanded public education.
A long-term analysis of over 8,000 samples revealed that SARS-CoV-2 infection and vaccine-induced antibody responses are long-lasting. Booster vaccination equalized differences in antibody concentration between participants with and without pre-existing immunity.
A recent study published in JAMA Network Open found that vaccinated adults with hematologic cancers were at high risk of severe COVID-19, even after receiving treatment. The study included 6,122 patients and showed no significant decline in severe cases through mid-2022.
Researchers developed a new recombinant flu vaccine called Hexaplex, which provided superior protection against H1N1 and H3N2 viruses in animal models. The vaccine's combination of six proteins from different groups resulted in strong antibody production and T-cell activation, offering broader immunity.
A recent study published in the American Journal of Obstetrics and Gynecology found that COVID-19 vaccination during pregnancy significantly reduces the risk of neonatal infections and premature birth. Vaccinated mothers' babies had lower rates of respiratory distress syndrome and days spent in the NICU compared to unvaccinated mothers.
A new study aims to enhance and prolong vaccine effectiveness by delivering adjuvants to white blood cells using lipid nanoparticles. The research, led by WVU professor Sharan Bobbala, has the potential to provide broader protection against evolving viruses and multiple diseases.
The study found that HPV vaccination coverage did not increase during the COVID-19 pandemic, indicating pandemic-related disruptions in initiating the vaccine. This suggests that efforts to promote HPV vaccination among young adults may need to be continued and strengthened.
A global vaccine safety study involving 99 million people found potential risks of myocarditis, pericarditis, Guillain-Barré syndrome, and cerebral venous sinus thrombosis after mRNA and viral vector COVID-19 vaccinations. The study's findings were made possible by the Global Vaccine Data Network.
A clinical study published in Microbiology Spectrum found that COVID-19 vaccines still provide a robust immune response in immunocompromised individuals, including cancer patients undergoing treatment. This finding is crucial for clinicians and patients, as it suggests vaccination can help prevent infection and disease progression.
Research from the National Institute of Allergy and Infectious Diseases found that COVID-19 vaccination during pregnancy can provide protection to infants for at least six months. Infants born to mothers who received both doses of a COVID-19 vaccine had higher antibody levels and greater protection from infection.
An experimental mRNA vaccine against CMV elicited promising immune responses, outperforming a previous vaccine candidate in preventing the virus from infecting epithelial cells. The new vaccine may protect adults against CMV, potentially preventing women from passing the infection to their babies during pregnancy.
A recent study published in JAMA found that bivalent mRNA COVID-19 vaccines were highly effective in protecting against SARS-CoV-2 infection and symptomatic COVID-19 in children and adolescents aged 5 to 17. The study, involving 2,959 participants, demonstrated the significant benefit of COVID-19 vaccination in this age group.
A large study of nearly 200,000 newborns in Sweden and Norway found that COVID-19 vaccination during pregnancy was not associated with any increased risks in newborn infants. In fact, babies born to vaccinated mothers had lower mortality rates and fewer serious complications.
A new study by NYU School of Global Public Health found that Americans who trusted their own doctors were more likely to get vaccinated against COVID-19. In contrast, trust in public officials had no significant impact on vaccination behavior. The researchers conclude that engaging the medical profession in communicating vaccine benefi...
A new study by Boston University School of Public Health found that many excess mortality rates from chronic illnesses were driven by COVID-19 infections, contradicting previous claims. The study estimated 1.2 million excess natural-cause deaths in US counties during the pandemic, with 163,000 uncounted COVID-19 deaths.
A study finds that individuals with biomedical expertise are influential anti-vaccine advocates on Twitter, sharing misinformation and sowing doubt. The research highlights the need for public education, credential verification, and disciplinary actions against health professionals spreading false information.
A large population-based study found that COVID-19 mRNA vaccines were not associated with increased neonatal adverse events in infants born between June 2021 and January 2023. The study included 94,000 vaccinated infants and 102,000 control infants, indicating a lower risk of serious health issues.
Researchers found a four-fold increase in immune response when people alternate arms during two-dose vaccinations. The study showed improved immunity to the original and omicron variants after three weeks and persisted beyond 13 months.
Two studies found people living with HIV in Catalonia have lower complete COVID-19 vaccination rates than those without HIV. However, they received more booster doses. Factors contributing to these disparities include previous SARS-CoV-2 diagnosis, socioeconomic situation and migration status.
La Jolla Institute researchers discovered that prior exposure to a common cold coronavirus partially protects mice from lung damage during a subsequent SARS-CoV-2 infection. Harnessing 'cross-reactive' T cells may lead to novel vaccines with broad, pan-coronavirus protection.
A new study finds that infants born full-term to mothers infected with COVID-19 during pregnancy are three times more likely to develop respiratory distress compared to uninfected infants. Vaccination prior to infection was found to be protective, reducing the risk by half.
A recent study of 2,261 infants found no significant adverse effects on neurodevelopment after in utero exposure to COVID-19 vaccination. The research suggests that maternal COVID-19 vaccination is safe for infant development up to 18 months.
A prospective cohort study of 220 pregnant individuals found that receiving three or more COVID-19 vaccine doses before delivery resulted in significantly higher cord anti-Spike antibody levels. Maternal antibody concentration was a more important factor than delivery gestational age in determining these levels.
Research reveals memory T cells formed after Omicron breakthrough infection provide enhanced immunity against future variants. The study suggests the immune system adapts to combat emerging strains, leading to higher chances of inducing memory T cell defenses.
A University of Alberta-led international network is studying very rare adverse events after vaccination, using cutting-edge techniques and unprecedented data from around the world. The goal is to enhance vaccine safety assessment and inform health authorities on the most appropriate type of vaccine for specific outbreak settings.
A new vaccine design has been developed by a UC Riverside-led research team, which uses preexisting immunity to the influenza virus to help kickstart the production of antibodies against SARS-CoV-2. The vaccine aims to speed up the immune response and provide better protection for people who still lack immunity to the coronavirus.
A large retrospective study found that vaccination against SARS-CoV-2 reduces the risk of persistent health problems in children after COVID-19. Vaccination provides stronger protection for adolescents, who are at higher risk of developing long COVID.
A UK study found that between a third and a half of the population had not received the recommended number of COVID vaccinations by summer 2022. The research suggests that this under-vaccination led to over 7,000 hospitalisations and deaths that might have been avoided with better vaccine coverage.
A new study suggests a universal coronavirus vaccine could have saved millions of lives and prevented suffering by offering some degree of protection against a range of strains. The study found that having a universal vaccine at the start of the pandemic would have been cost-saving even with low efficacy rates.
Researchers designed a synthetic antigen with high expression levels and stability, offering potential for quick adaptation to new variants. The vaccine candidate triggered strong immune response in animal models and showed enhanced protective efficacy.
A nationwide cohort study found that COVID-19 survivors exhibit lower all-cause mortality and congestive heart failure but higher acute myocarditis and deep vein thrombosis risks. Younger, non-vaccinated patients with preexisting cardiovascular risk factors face elevated cardiovascular complications.
Researchers have successfully used mRNA technology to correct a rare genetic disease in mice, demonstrating its potential therapeutic use. The treatment corrected the lethal consequences of the disease and restored glutathione metabolism.
A recent study found that only 18% of US hospitals reported consistent COVID-19 reporting directives across government agencies. The research highlights the need for standardized protocols and automation to improve data submission efficiency and enhance public trust in healthcare.
Researchers at Karolinska Institutet have developed a nasal spray with IgA antibodies that can protect mice from SARS-CoV-2 infection. The treatment significantly diminished virus load in infected mice and showed stronger binding to the spike protein compared to original IgG antibodies.
A new study reveals that people with sickle cell disease are nearly two times less likely to get vaccinated against COVID-19 compared to those without the disease. Vaccination rates were particularly low in children and teens with sickle cell disease, who face a higher risk of hospitalization and death if infected.
Researchers at Duke-NUS Medical School have discovered a potential intranasal vaccine candidate that provides improved, longer-lasting immunity against COVID-19. The vaccine boosts mucosal antibody response and enhances long-term immune protection through preferential induction of airway-resident T cells and central memory T cells.
A real-world study found that COVID-19 vaccines are highly effective in protecting children and adolescents from infection, with 98% reduced risk during the delta variant phase. Vaccine effectiveness slightly declined during the omicron wave, but still provided strong protection against severe illness and cardiac complications.
The BA.2.86 omicron subvariant can infect human lung cells more efficiently than previous omicron variants, raising concerns about potential severe disease symptoms. While bivalent mRNA vaccines can neutralize BA.2.86, the efficiency is reduced, emphasizing the importance of getting a newer booster vaccine.
A study of over 5,000 adults found that acute hospital care at home (AHCaH) is associated with low mortality, escalation, and readmission rates among medically complex and socially vulnerable patients. AHCaH was also linked to improved experiences and physical activity levels.
A machine-learning enabled risk assessment model detects 72.8% of variants causing over 1,000 cases per million people within a week, increasing to 80.1% after two weeks. The model identifies key factors such as variant spike mutations and early infection trajectories.
Researchers found that vaccinated B cell-deficient individuals have a robust T cell response to SARS-CoV-2, despite lack of anti-spike antibodies, resulting in markedly reduced rates of hospitalization and severe COVID-19. This study provides reassuring evidence for immunocompromised patients to get vaccinated.
Researchers have developed a mineral coating that maintains mRNA activity for up to six months at room temperature. This breakthrough enables the storage of mRNA therapeutics like COVID-19 vaccines on medical shelves, bridging the gap between rich and poor communities.
A new study found that COVID-19 vaccine effectiveness decreases after six months, highlighting the importance of continued booster shots. Researchers analyzed over 10 million cases and discovered a significant reduction in mortality rates among vaccinated adults.
A new study finds that most US parents intend to vaccinate their infants and young children against COVID-19, influenza, and respiratory syncytial virus (RSV), with 40% planning to vaccinate against COVID-19. The study also highlights the growing concern of vaccine hesitancy and its potential impact on public health.
Scientists have developed a new system to display epitopes in mammal cells for immunization studies, potentially speeding up the immunization process. This method allows for targeted immune responses against specific viral proteins without the need to purify antigens.
Two Melbourne-made COVID-19 vaccines demonstrated strong boosting capabilities against SARS-CoV-2 variants in a Phase 1 clinical trial. The vaccines focus the immune response on the receptor binding domain, potentially providing a more efficient approach to boost immunity.
A major study found that patients with inflammatory conditions can boost their antibody response to a COVID-19 booster vaccination by interrupting their treatment for two weeks. The improved protection lasts for six months, and patients who interrupted treatment reported more flare-ups but most were self-managed.